Empagliflozin open ring impurity arises from hydrolytic cleavage of the parent drug's pyran ring, yielding a linear structure with a chloromethyl substituent, a vicinal diol moiety, and a carboxylic acid ester. The compound retains the aromatic core but exhibits altered stereochemistry at the C-6 position. This impurity functions as an HPLC reference standard for quantifying degradation pathways in empagliflozin synthesis and stability studies.
On RequestC1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]([C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O)Cl
InChI=1S/C23H29ClO8/c24-18-6-3-14(20(27)22(29)23(30)21(28)19(26)11-25)10-15(18)9-13-1-4-16(5-2-13)32-17-7-8-31-12-17/h1-6,10,17,19-23,25-30H,7-9,11-12H2/t17-,19+,20+,21+,22-,23-/m0/s1
RKDDAJYLEWTGMU-PNZPLEPNSA-N